Teleflex Incorporated (NYSE:TFX) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its position in shares of Teleflex Incorporated (NYSE:TFX) by 6.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,376 shares of the medical technology company’s stock after selling 282 shares during the period. Commonwealth Equity Services LLC’s holdings in Teleflex were worth $920,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Hantz Financial Services Inc. acquired a new position in shares of Teleflex during the second quarter worth $252,000. iA Global Asset Management Inc. grew its stake in shares of Teleflex by 3.6% during the second quarter. iA Global Asset Management Inc. now owns 3,249 shares of the medical technology company’s stock worth $683,000 after purchasing an additional 113 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Teleflex by 621.3% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 30,698 shares of the medical technology company’s stock valued at $6,457,000 after acquiring an additional 26,442 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Teleflex by 1.9% in the second quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock valued at $584,000 after acquiring an additional 53 shares in the last quarter. Finally, Speece Thorson Capital Group Inc. boosted its stake in Teleflex by 33.0% in the second quarter. Speece Thorson Capital Group Inc. now owns 48,046 shares of the medical technology company’s stock valued at $10,106,000 after acquiring an additional 11,925 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Price Performance

Shares of NYSE:TFX opened at $241.50 on Wednesday. The company has a 50-day simple moving average of $234.07 and a 200-day simple moving average of $220.08. Teleflex Incorporated has a one year low of $177.63 and a one year high of $257.85. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 2.58. The stock has a market capitalization of $11.38 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.20 and a beta of 1.16.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.33 by $0.09. The firm had revenue of $749.70 million during the quarter, compared to analysts’ expectations of $762.98 million. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the company posted $3.41 earnings per share. On average, analysts predict that Teleflex Incorporated will post 13.97 EPS for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Thursday, August 15th were issued a dividend of $0.34 per share. The ex-dividend date was Thursday, August 15th. This represents a $1.36 annualized dividend and a yield of 0.56%. Teleflex’s dividend payout ratio is currently 21.83%.

Insider Buying and Selling

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the transaction, the director now directly owns 5,496 shares in the company, valued at $1,313,159.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.43% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TFX has been the subject of several research analyst reports. Truist Financial upped their price objective on shares of Teleflex from $240.00 to $247.00 and gave the company a “hold” rating in a research note on Monday, August 5th. Royal Bank of Canada upped their price objective on shares of Teleflex from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Finally, Stephens upped their price objective on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teleflex currently has an average rating of “Moderate Buy” and a consensus target price of $265.57.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.